74 results about "Pseudomonas aeruginosa Infections" patented technology

The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

Method and apparatus for using computer controlled, fiber-coupled laser delivery of treatment specific wavelength, intensity and duration of UV irradiation to control bacterial, fungal, viral and mold infections in bodily cavities, fluids and external applications. The method of treatment is focused on DNA breakdown beyond repair by natural DNA repair mechanisms of the pathogen, with less than damaging doses to tissues being treated, thus avoiding mutagenicity and carcinogenicity. The minimal intensity and duration and exposure area of any given surface of tissue to be treated is to be pre-determined by tissue and pathogen testing to optimize the therapeutic ratio. External applications include specifically Trichophyton Rubrum (toenail fungus) through the nail and Pseudomonas Aeruginosa infections in burns and elsewhere.

The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

The present invention relates to novel diagnostic, prognostic and therapeutic reagents for infection of an animal subject such as a human by Pseudomonas aeruginosa, and conditions associated with such infections, such as, for example, an acute clinical exacerbation in a cystic fibrosis (CF) subject. In particular, the present invention relates to methods for diagnosing / prognosing an infection by P. aeruginosa in a subject comprising detecting the presence or amount of one or more proteins of P. aeruginosa or a fragment or epitope thereof or an antibody thereto in a sample from the subject.

The present invention relates to polypeptides of Pseudomonas aeruginosa which may be used to prevent, diagnose and / or treat Pseudomonas aeruginosa infection.

The present invention relates to assays, kits and oligonucleotides for the detection of Pseudomonas aeruginosa for a fast, sensitive and reliable detection of Pseudomonas aeruginosa in a species- and serotype-specific manner. In particular, the present invention provides an assay for the serotype-specific detection of Pseudomonas aeruginosa, a kit for the serotype-specific detection of Pseudomonas aeruginosa, as well as oligonucleotides useful in such assay or kit. The present invention further relates to the use of Pseudomonas aeruginosa serotype specific antibodies for serotype specific treatment of Pseudomonas aeruginosa infection in a patient detected for said specific Pseudomonas aeruginosa serotype with such an assay or kit.

Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa, and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa, and said antibodies are protective against infection caused by P. aeruginosa. These antibodies as well as pharmaceutical composition comprising them are useful for the treatment of indications caused by P. aeruginosa infection.

The invention relates to application of 3-methyladenine in preparation of a medicine for preventing acute pneumonia induced by pseudomonas aeruginosa, and belongs to the technical field of biomedicine. Experimental research shows that before pseudomonas aeruginosa infection, the survival rate of experimental animals can be increased by using 3-methyladenine, and meanwhile, host tissue damage caused by excessive inflammatory immune response is avoided along with pathology reduction and reduction of inflammatory cytokines and in-lung bacteria load; and the increasing drug resistance of bacteria to existing antibiotics due to improper use of the antibiotics can be avoided, and the application prospect is wide.

A combination of an antibody and other therapeutic that work together in vivo against a pathogenic microbe. The combination can include the antibody with an antibiotic, and / or a therapeutic against adisease. The combination can attack the pathogenic microbe with an efficiency more than either of the components alone, with a synergistic effect, or an effect moderated by one or more modes of actionnot existing with administration of either the antibody or therapeutic alone.

Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.

The present invention relates to a nucleic acid aptamer ETA01 of Pseudomonas aeruginosa exotoxin A and its application. The sequence of the nucleic acid aptamer ETA01 includes: 5'-TGCAACTCCAACTAACCATGTGTTCAT CTGAGGGTGGTCTTCGCA-3'. The nucleic acid aptamer ETA01 of the present invention can bind to Pseudomonas aeruginosa exotoxin A with high affinity and high specificity, and use the nucleic acid aptamer ETA01 as the recognition element of Pseudomonas aeruginosa exotoxin A to establish Pseudomonas aeruginosa The detection method of bacterial exotoxin A, the preparation of detection reagents, and the development of exotoxin A antagonistic drugs can be used in the diagnosis and treatment of Pseudomonas aeruginosa infection and the research on the biological function of Pseudomonas aeruginosa exotoxin A. The method has the advantages of simplicity, rapidity and good characteristics.

Provided is a novel prophylactic and / or therapeutic agent for Pseudomonas aeruginosa infection. It was found that a bacterium belonging to the genus Enterococcus can prevent and / or treat Pseudomonas aeruginosa infection. The prophylactic and / or therapeutic agent for Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus. A medicine for prevention and / or treatment of Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus. A food for prevention and / or treatment of Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus.

The invention discloses an application of PA4608 protein as a target in preparing antibacterial drugs. By constructing a PA4608 (mapZ) site mutant strain mapz_R13A and a mapZ whole gene knockout mutant and by utilizing a nematode-quick killing infection model, a scratch cell model and a mouse abdominal infection model for study, the invention first puts forwards that the c-di-GMP binding site of PA4608 protein plays an important regulatory role in pseudomonas aeruginosa infection process, puts forwards that the site is a key site for the pathogenicity of the pseudomonas aeruginosa, and furtherputs forwards a new target, namely a c-di-GMP receptor PA4608 used for preventing and / or treating the pseudomonas aeruginosa. The invention provides an important theoretical basis for the developmentof new antibacterial drugs, especially for the design of new antibacterial drugs based on c-di-GMP receptor induction mechanism, provides an important theoretical reference for the prevention and clinical treatment of pseudomonas aeruginosa infection, and has important practical significance.